Daiichi Sankyo Co., Ltd. Sponsored ADR (DSNKY)
OTC PINK OTC PINK Primary 
XFRA 
New Strong Sell Stocks for February 25th
DSNKY, LPX and RAL have been added to the Zacks Rank #5 (Strong Sell) List on February 25, 2026.
Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued
Daiichi Sankyo shares are potentially deeply undervalued, but the near-term outlook hinges on pivotal clinical trial outcomes, notably the AVANZAR study. Enhertu continues to grow well, and Datroway is off to a good start in breast cancer, but upcoming lung cancer readouts are critical for unlocking multi-billion-dollar revenue potential. Recent clinical delays, mixed pipeline results, and management's push toward a more independent company with a deeper pipeline raise execution and M&A risks.
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript
Daiichi Sankyo Company, FQ2 2026 Earnings Call October 31, 2025 2:30 AM ET Company Participants Hiroyuki Okuzawa - President, CEO, Representative Director Joseph Kenneth Keller - President, CEO Ken Takeshita - Head of Research and Development Unit Conference Call Participants Kentaro Asakura Ladies and gentlemen, we would like to start FY2025 Q2 financial results presentation. My name is Asakura, in charge of Corporate Communication.
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) and Zoetis (ZTS).
Approaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO
Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S. tariffs.
Incoming Daiichi Sankyo CEO shares business roadmap going forward
Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with AstraZeneca and Merck.
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
